STAT

DECEMBER 14, 2024

Novo Holdings, the parent company of Novo Nordisk, can proceed with its planned $16.5 billion acquisition of Catalent, a leading contract drug manufacturer, after U.S. regulators declined to challenge the deal following months of scrutiny. The companies expect to close the transaction in the next several days, after a deadline passed for the U.S. Federal Trade Commission to raise objections and other regulatory conditions were fulfilled, according to statements issued by Novo Nordisk and Catalen

117

117

Pharmacy Times

DECEMBER 14, 2024

Emerging research in triple-negative breast cancer highlights the promise of molecular-based approaches to improve treatment outcomes.

65

65

STAT

DECEMBER 14, 2024

A U.S. government agency warned Sanofi that it faces sanctions over plans to change the way payments are made to most hospitals participating in a drug discount program, the third time in recent months that a major pharmaceutical company has been threatened with such a step. In a Dec. 13 letter , the Health Resources & Services Administration said that if Sanofi proceeds with its plan, the company could be terminated from the 340B Drug Discount Program.

Hospitals 111

Hospitals Pharmaceutical Companies Pharmaceutical Companies 111

Pharmacy Times

DECEMBER 14, 2024

Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.

Chemotherapy 65

Chemotherapy 65

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

STAT

DECEMBER 14, 2024

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.

Insurance 90

Insurance 90

Pharmacy Times

DECEMBER 14, 2024

AI-powered analysis of mammography images can identify women at high long-term risk of breast cancer, enabling targeted prevention strategies.

65

65

Pharmacy Times

DECEMBER 14, 2024

Advancements in prevention address cancer risk in high-risk patients and BRCA mutation carriers.

Vaccines 65

Vaccines 65